MarketMoodz
Dexcom Wins FDA OTC Clearance for Stelo in Children
The FDA reportedly cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use in children aged 2 and older who do not use insulin, expanding at-home glucose monitoring into pediatric care. If confirmed, the move follows Stelo’s adult OTC clearance earlier in 2024 and could broaden Dexcom’s consumer market beyond prescription users.
Key Takeaways
- FDA is reported to have cleared Dexcom’s Stelo for OTC use in children age 2+ who are not on insulin.
- Stelo provides glucose readings every 15 minutes and pairs with a smartphone or caregiver device.
- The sensor is marketed to last up to 15 days per wear cycle, though pediatric wear may vary.
- This would be the first OTC CGM authorized for non-insulin-using children, potentially enlarging Dexcom’s addressable market.
- Benzinga reported Dexcom stock at about $73.71 per share at publication, down roughly 2%.
People Involved
- No specific individuals mentioned
Entities Involved
- Dexcom Inc. (DXCM)Manufacturer of the Stelo Glucose Biosensor System
- U.S. Food and Drug Administration (FDA)Regulatory authority reportedly granting OTC clearance
MarketMoodz Analysis
For investors, an OTC pediatric clearance for Stelo would widen Dexcom’s consumer footprint beyond adults and prescription users, increasing potential unit volumes and recurring sensor sales. OTC availability simplifies access — no prescription or specialist visit — which can accelerate adoption among families monitoring prediabetes or glucose trends in children; that potential could translate into higher revenue over time, but hinges on payer responses and whether families pay out-of-pocket or seek reimbursement.
This decision — reported to rely on real-world evidence and pediatric/adult study data — fits a broader regulatory trend toward leveraging RWE for device authorizations and expanding OTC digital-health products. Historically, CGM adoption grew after payer coverage and clinician endorsement increased; OTC access removes a barrier but doesn’t guarantee reimbursement. Investors should watch for an official FDA notice or Dexcom press release, subsequent payer policies for pediatric OTC CGMs, published pediatric performance and safety data, and any updates to Dexcom’s sales guidance that quantify the pediatric opportunity.
Source: Original Article